Thalidomide Celgene (thalidomide) Important Safety Information from Celgene as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 19/04/2013

Problem Or Issue:
Important Safety Information communication from Celgene on the risk of haematologic second primary malignancies in patients treated with thalidomide.

Important Safety Information for Haematologists - Thalidomide Celgene (thalidomide)

Important Safety Information for Pharmacists - Thalidomide Celgene (thalidomide)

« Back